Effects of Certain Terminations. In the event of termination of this Agreement
Effects of Certain Terminations. If (i) Galderma terminates this Agreement in its entirety pursuant to Section 12.2, or (ii) NovaBay terminates this Agreement pursuant to Section 12.3 or Section 12.4, then at NovaBay’s election:
Effects of Certain Terminations. In the event of termination of this Agreement pursuant to Section 9.2, 9.3, or 9.4, the licenses granted to Licensee under Sections 2.1, 2.2 and 2.3 shall terminate, but Licensee may elect to have any then-existing Sublicenses survive as direct licenses from Licensors (provided that the applicable Sublicensees are in good standing thereunder and are not in material breach of any material obligation or term under this Agreement including Section 2.4) and such survival will be accepted by Licensors. Each Sublicense surviving as a direct license as set forth herein will remain in full force and effect with Licensors as the licensor or sublicensor instead of Licensee, but the duties and obligations of Licensors under such surviving Sublicenses will not be greater than the duties of Licensors under this Agreement, and the rights of Licensors under such surviving Sublicenses will not be less than the rights of Licensors under this Agreement.
Effects of Certain Terminations. In the event of termination of this Agreement by Adaptive pursuant to [***], or by GNE pursuant to [***], in addition to those provisions surviving under Section 16.6.1(f), upon such termination the following terms of this Section 16.6.2 shall apply:
Effects of Certain Terminations. If THERAGENEX electively terminates this Agreement pursuant to Section 9.2(c) or ADVENTRX terminates this Agreement pursuant to Section 9.2(a) or (b), then upon such notice of termination:
Effects of Certain Terminations. Upon termination of this Agreement by Cornerstone pursuant to Section 10.2 or Section 10.4 or by Targacept pursuant to Section 10.3, the following provisions shall apply.
Effects of Certain Terminations. Upon termination of this Agreement by Licensor pursuant to Section 9.2, 9.4 or 9.5, or by IMI pursuant to Section 9.3:
Effects of Certain Terminations. 12.5.1 In the event that JPI terminates this Agreement in its entirety prior to completion of all Research Programs, JPI […***…]* during the […***…]month period beginning on JPI’s delivery of notice of termination to Arcturus as specified in the Joint Research Plan and […***…] (or, if less than […***…] months […***…], such […***…] obligation being subject to […***…]. Arcturus will use Commercially Reasonable Efforts to […***…]. Notwithstanding the foregoing, in the event that JPI delivers Arcturus a written notice of termination of this Agreement prior to […***…], JPI shall […***…] pursuant to this Section 12.5.1.
Effects of Certain Terminations. If KCI electively terminates this Agreement in its entirety pursuant to Section 10.2(a) or NovaBay terminates this Agreement pursuant to Section 10.2(b) or 10.2(c), then:
Effects of Certain Terminations. If this Agreement is terminated, in its entirety or as to a particular Product or region, by Astellas pursuant to Section 13.2.1 or 13.2.2, or by Maxygen pursuant to Section 13.3, 13.4.1 or 13.4.2, then the provisions of this Section 13.6 shall apply (subject to Section 13.4.1(c) with respect to terminations pursuant to Section 13.4.1, and subject to Section 13.4.2(e)(ix) or (x), as applicable, with respect to terminations pursuant to Section 13.4.2), provided that in case of termination only as to a particular Product or region, Section 13.6 shall apply only to such Product or region (i.e., North America, Europe, and/or Asia), and further provided that this Section 13.6 shall not apply to expiration of this Agreement (nor to termination by Astellas under Section 13.3). Notwithstanding the foregoing, in the event of termination by Astellas pursuant to Section 13.2.2, Sections 13.6.1 and 13.6.2 shall not apply with respect to the Compound(s) and corresponding Product(s) for which Adverse Safety/Tox Results were obtained.
